Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | GBA1 | P04062 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.44 |
| ▸ | TUBB | P07437 | 1/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16139155 | 0.95 | MAPT (0.47) | MAPTTP53LMNAABCG2MEN1 | |
| SCHEMBL3602136 | 0.91 | ABCG2 (0.47) | MAPTTP53LMNAABCG2MEN1 | |
| SCHEMBL3413002 | 0.88 | ABCG2 (0.54) | MAPTTP53LMNAABCG2MEN1 | |
| SCHEMBL3409105 | 0.88 | ABCG2 (0.52) | MAPTTP53ABCG2MEN1KMT2A | |
| SCHEMBL3600310 | 0.88 | ABCG2 (0.52) | MAPTTP53LMNAABCG2MEN1 | |
| SCHEMBL3592180 | 0.87 | MAPT (0.55) | MAPTTP53LMNAABCG2MEN1 | |
| SCHEMBL19719713 | 0.86 | ABCG2 (0.46) | MAPTTP53LMNAABCG2MEN1 | |
| SCHEMBL14861915 | 0.85 | ABCG2 (0.56) | ABCG2MEN1KMT2ARAB9ADPP4 | |
| SCHEMBL14861582 | 0.82 | LMNA (0.48) | MAPTLMNAABCG2 | |
| SCHEMBL29648256 | 0.82 | LMNA (0.48) | MAPTLMNAABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962634-B2 | 4-amino-3-arylamino-6-arylpyrazolo[3,4-d) pyrimidine derivatives, methods for their preparation and their use as antiviral agents | DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2015-02-24 | — | — | US | claimed |
| US-20180044341-A1 | 4-AMINO-3-PHENYLAMINO-6-PHENYLPYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES FOR USE AS BCRP INHIBITORS IN THERAPEUTIC TREATMENTS | DRITTE PATENTPORTFOLIO BETEILIGUNGS-GESELLSCHAFT MBH & CO. KG (DE) | 2018-02-15 | — | — | US | disclosed |
| US-9790225-B2 | 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances | SCANDION ONCOLOGY A/S (DK) | 2017-10-17 | — | — | US | disclosed |
| US-8962634-B2 | 4-amino-3-arylamino-6-arylpyrazolo[3,4-d) pyrimidine derivatives, methods for their preparation and their use as antiviral agents | DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2015-02-24 | — | — | US | disclosed |
| US-20140296259-A1 | 4-Amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances | SCANDION ONCOLOGY A/S (DK) | 2014-10-02 | — | — | US | disclosed |
| EP-2049540-B1 | 4-AMINO-3-ARYLAMINO-6-ARYLPYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THEIR USE AS ANTIVIRAL AGENTS | DRITTE PATENTPORTFOLIO BETEILI (DE) | 2010-12-22 | — | — | EP | disclosed |
| US-20100010018-A1 | 4-Amino-3-Arylamino-6-Arylpyrazolo[3,4-D) Pyrimidine Derivatives, Methods for their Preparation and their Use as Antiviral Agents | DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296259-A1 | 4-Amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives, their manufacture and their use as antiviral active substances | POLL, RPP30, EIF2AK2 | MAPT 3534/4885TP53 2757/4885LMNA 1817/4885 |
| US-20180044341-A1 | 4-AMINO-3-PHENYLAMINO-6-PHENYLPYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES FOR USE AS BCRP INHIBITORS IN THERAPEUTIC TREATMENTS | ABCB1, ABCC1, MPHOSPH6 | MAPT 2237/4885TP53 1423/4885LMNA 4295/4885 |
| US-20100010018-A1 | 4-Amino-3-Arylamino-6-Arylpyrazolo[3,4-D) Pyrimidine Derivatives, Methods for their Preparation and their Use as Antiviral Agents | PNP, TYMP, EIF2AK2 | MAPT 4098/4885TP53 3006/4885LMNA 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.